IL-6 pathway in the liver: From physiopathology to therapy

J Hepatol. 2016 Jun;64(6):1403-15. doi: 10.1016/j.jhep.2016.02.004. Epub 2016 Feb 8.

Abstract

Interleukin 6 (IL-6) is a pleiotropic four-helix-bundle cytokine that exerts multiple functions in the body. In the liver, IL-6 is an important inducer of the acute phase response and infection defense. IL-6 is furthermore crucial for hepatocyte homeostasis and is a potent hepatocyte mitogen. It is not only implicated in liver regeneration, but also in metabolic function of the liver. However, persistent activation of the IL-6 signaling pathway is detrimental to the liver and might ultimately result in the development of liver tumors. On target cells IL-6 can bind to the signal transducing subunit gp130 either in complex with the membrane-bound or with the soluble IL-6 receptor to induce intracellular signaling. In this review we describe how these different pathways are involved in the physiology and pathophyiology of the liver. We furthermore discuss how IL-6 pathways can be selectively inhibited and therapeutically exploited for the treatment of liver pathologies.

Keywords: Cancer; Inflammation; Interleukin-6; Interleukin-6-receptor; Liver regeneration; Trans-signaling.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute-Phase Reaction
  • Animals
  • Humans
  • Insulin Resistance
  • Interleukin-6 / physiology*
  • Interleukin-6 Inhibitors
  • Liver / physiology
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / etiology*
  • Liver Regeneration
  • Receptors, Interleukin-6 / physiology
  • STAT3 Transcription Factor / physiology
  • Signal Transduction

Substances

  • Interleukin-6
  • Receptors, Interleukin-6
  • STAT3 Transcription Factor
  • Interleukin-6 Inhibitors
  • STAT3 protein, human